Matt Osman is the co-founder and CEO of Polyphron, a company building high-fidelity human tissues from induced pluripotent stem cells (iPSCs) as both therapeutic products and a scalable data engine for predictive biology. Polyphron’s approach focuses on generating causal, human-relevant datasets that capture how molecular interventions translate into functional outcomes, enabling the development of more predictive models of human health and disease .Osman is a serial exited founder whose work spans artificial intelligence and the life sciences. He previously founded and exited Legit AI, a machine learning company applied to the life sciences, and later built and sold Treat, a generative AI company. His broader work has centered on applying computational approaches to domains where high-quality, real-world data is the primary bottleneck.He began as a barrister before joining a leveraged credit hedge fund as a trader, bringing a multidisciplinary perspective across finance, law, and technology to his work in biology.